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Abstract: Observational studies which evaluate effectiveness are often viewed with skepticism 
owing to the fact that patients are not randomized to treatment, meaning that results are more 
prone to bias. Therefore, randomized controlled trials remain the gold standard for evaluating 
treatment effectiveness. However, it is not always possible to conduct randomized trials. This 
may be due to financial constraints, for example, in identifying funding for a randomized trial 
for medicines that have already gained market authorization. There can also be challenges 
with recruitment, for example, of people with rare conditions or in hard-to-reach population 
subgroups. This is why observational studies are still needed. In this manuscript, we discuss 
how researchers can mitigate the risk of bias in the most common type of observational study 
design for evaluation of treatment effectiveness, the cohort study. We outline some key issues 
that warrant careful consideration at the outset when the question is being developed and the 
cohort study is being designed. We focus our discussion on the importance of deciding when 
to start follow-up in a study, choosing a comparator, managing confounding and measuring 
outcomes. We also illustrate the application of these considerations in a more detailed case study 
based on an examination of comparative effectiveness of two antidiabetic treatments using data 
collected during routine clinical practice.
Keywords: epidemiology, therapeutics, diabetes mellitus, public health, effectiveness
Introduction
The randomized controlled trial (RCT) is considered the gold standard design for 
examining the effectiveness of a treatment.1 This is because randomization increases 
the likelihood that treatment allocation is undertaken independently of both known 
and unknown patient characteristics, although there remains a possibility of chance 
imbalances.2 This chance is inversely proportional to the sample size being studied.3 
Such baseline imbalances associated with the outcome under study can confound the 
findings, leading to biased estimates of effectiveness.
Despite growing interest in the use of observational studies to evaluate effectiveness, 
their application remains contentious.4 This is because the absence of randomization 
means that treatment choice is usually influenced by the clinician’s perception of the 
effectiveness of the treatments being considered.5 Hence, baseline imbalances that can 
bias estimates of treatment effectiveness are almost always present. A comparison of 
outcomes across treated and untreated individuals in an observational study may lead 
one to erroneously conclude that treatment is not effective, when in fact the treatment 
may have been selectively given to those with the worst prognosis.5
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Despite these challenges, observational studies of effec-
tiveness do offer opportunities to examine questions that 
may not be possible using RCTs.6 First, they can be used 
to examine the effectiveness of medication that has already 
been granted marketing authorization and for which funding 
for further trials may be limited. Second, they can allow the 
examination of effectiveness for rare treatment indications. 
Third, a large observational study can be more representa-
tive of a clinical population and less prone to selection bias 
than a trial. Thus, it can allow investigation of the external 
validity of trial results in more diverse populations, such as 
ethnic minority groups and elderly patients, who are often 
underrepresented in conventional trials.7
In this paper, we focus on use of cohort studies to evalu-
ate effectiveness, where individuals are followed up from 
exposure to a treatment for the development of an outcome 
of interest. In particular, we will outline important consid-
erations in cohort study design that can help to mitigate the 
risk of bias and conversely help to identify research questions 
of clinical effectiveness that are more suited to investigation 
using such a design. We then illustrate the application of these 
considerations in depth with reference to a case study based 
on our own completed work, which examined the comparative 
effectiveness of two antidiabetic treatments. Alternative study 
designs, such as self-controlled case series and case–control 
studies,8,9 are well described in the literature8,9 and will not 
be covered in this article.
Important considerations in the design 
of cohort studies to evaluate treatment 
effectiveness
In this section, we discuss four important aspects to con-
sider when designing cohort studies to evaluate treatment 
effectiveness: when to start follow-up, choosing compara-
tors, identification and measurement of confounding, and 
ascertainment of the outcome.
Start of follow-up
In cohort studies, individuals are ideally followed up from 
when they are first initiated on a treatment (new-user design).7 
However, this is not always possible, and some studies include 
individuals who have already been receiving the treatment 
before the start of follow-up (prevalent user design). There 
are advantages and disadvantages to both approaches. In 
the new-user design, by excluding the prevalent users (left 
truncation) a “prevalent user” bias is eliminated which can 
be linked to the fact that they have already “survived” a prior 
period of treatment use without any negative consequences. 
New-user design allows for the adjustment of confounders at 
baseline, when the decision was made to initiate treatment, 
thus helping to eliminate bias.7,10 These biases are most 
relevant when the risk of an outcome of interest is known to 
be highest in the early stages of treatment. An example of 
prevalent user bias was seen in studies which demonstrated 
that hormone replacement therapy (HRT) prevented coronary 
heart disease, whereas subsequent trials found HRT to be 
harmful.11 The observational studies included prevalent users 
who were taking HRT before study follow-up and had already 
survived a period of use without any harm. They had a lower 
likelihood of cardiovascular outcomes at initiation of study 
follow-up, which led to the bias seen in the risk estimates 
that suggested a protective effect of HRT.12
Restricting inclusion to “new users” only does have 
limitations. It reduces the sample size of cohort studies 
and may limit long-term follow-up (right truncation).11 
Provided the risk of biases and potential directionality are 
carefully considered, the evaluation of prevalent users can 
still be useful.13 For example, even though estimates for 
cardiovascular outcomes were biased in the HRT obser-
vational study, effectiveness estimates produced for other 
outcomes where risks were cumulative over time, such as 
colon and breast cancer, were unbiased and similar to the 
trials.13 In practice, it can sometimes be helpful to split 
the cohort into “new users” and “prevalent users” and 
analyze treatment effectiveness separately in each group, 
so that the limitations of left and right truncation can be 
acknowledged (Table 1).13
Choice of comparators
Although it is common practice in RCTs, estimating the 
effectiveness of treatments by comparing treated and 
untreated individuals in a cohort study can lead to bias as 
treatment may be indicated only for those with a specific 
prognosis. The results may suggest that treatment is inef-
fective if an untreated group has a better prognosis or, 
conversely, may exaggerate effectiveness if the untreated 
group has a worse prognosis. This type of bias, which often 
occurs in observational studies, is known as channeling bias 
or confounding by indication, and arises when the indication 
for choosing a particular treatment also affects the outcome.5 
Treated and untreated groups commonly differ in terms 
of disease severity, which can be difficult to measure in a 
cohort study.5 For example, using a cohort study design, 
Freemantle et al investigated the effectiveness of using 
spironolactone in reducing mortality in patients with severe 
heart failure treated in clinical practice.5 In contrast to the 
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randomized aldactone evaluation study (RALES) clinical 
trial, which found that spironolactone reduced mortality,14 
their observational study found a lower mortality in the 
untreated group than in those treated with spironolactone.5 
These contrasting results were explained by the difference 
in disease severity across the two groups, as spironolactone 
was primarily prescribed to those with more severe heart 
failure and the worst prognosis.5
While it may often be difficult to estimate the effect of 
treatment against no treatment based on data from clinical 
practice owing to channeling bias, Smeeth et al successfully 
replicated the findings from large trials in their cohort study. 
They showed that statin use was effective in reducing vascular 
outcomes compared to non-use.15 In this instance, they were 
able to match statin users to non-users with similar disease 
severity and hence mitigate the risk of bias.
Another approach in cohort study design that can often 
help to yield more accurate estimates involves the inclu-
sion of an active comparator group, if the clinical question 
allows. For example, consider a cohort study comparing two 
Table 1 Important considerations in the design of cohort studies to evaluate treatment effectiveness and how to mitigate the risk of 
bias
Consideration Bias Definition Problem Approach that can help
Starting follow-up Prevalent user bias Bias that arises from the 
inclusion of individuals 
who have already initiated 
treatment prior to inclusion 
in study
Prevalent users survived a period of 
exposure before the study and may 
be at lower risk of an event
New-user design
Starting follow-up Incomplete follow-
up bias
Bias that arises owing to too 
short a period of follow-up for 
an outcome
If an event is due to a cumulative 
effect of a treatment, insufficient 
follow-up may not allow enough time 
for the event to occur
Prevalent user design
Comparator choice Channeling bias Bias that arises when the 
clinical indication for choosing 
a particular treatment also 
affects the outcome
If there is channeling bias then 
an effectiveness estimate may be 
biased, with a directionality based on 
whether the comparison group has 
better or worse prognosis
Use of an active comparator 
where there is equipoise in 
treatment choice
Identification and 
measurement of 
confounders
Confounding bias Bias that arises when factors 
that affect both treatment 
choice and outcome are not 
accounted for
the directionality of this bias can 
be unpredictable and will depend 
on both accurate identification and 
measurement of confounders, as 
well as the extent of unmeasured 
confounding
Identification, accurate 
measurement and controlling 
for confounding
outcome 
ascertainment
Reporting bias Bias that arises owing to an 
imbalance in recording of an 
outcome across treatment 
groups
this can lead to a treatment 
appearing more or less effective 
when, in fact, the outcomes are 
simply recorded differently across 
treatment groups
Careful consideration and 
understanding of how an 
outcome might be detected 
and recorded in clinical 
practice
outcome 
ascertainment
Attrition bias Bias that arises owing to 
an imbalance in duration of 
follow-up across treatment 
groups
this can lead to lower numbers 
for an outcome in the group with 
shorter follow-up time
Ensuring comparison groups 
have similar follow-up time 
across which an outcome can 
realistically be recorded
alternative first-line antihypertensive agents, the angiotensin-
converting enzyme inhibitors ramipril and perindopril, for 
reducing blood pressure. The choice of either ramipril or 
perindopril is unlikely to be driven by many prognostic factors 
other than prescriber preferences or local formulary policy, 
and hence patients are likely to have similar disease severity 
at baseline.16 However, such a study is limited to providing 
estimates of the relative effectiveness of the two treatments 
only, and not of the effectiveness of treatment compared to 
no treatment.
Identification and measurement of confounding
In clinical practice, scenarios where there is complete base-
line balance in disease severity are rare, and the design and 
analysis of most observational studies of effectiveness will 
need to actively remove sources of potential confounding 
bias.17 This involves the identification of all factors that 
cause the outcome and are associated with treatment choice, 
but are not on the treatment–outcome pathway. This can be 
achieved with visual maps called direct acyclic graphs.18,19 
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Once  confounders have been identified, several analytical 
approaches can be applied to remove the influence of con-
founders on effect estimates, such as propensity-score based 
methods and standard multivariable regression methods.17,20 
Patorno et al used propensity score matching in a large 
cohort study examining the antidiabetic agent canaglifozin. 
They demonstrated that canaglifozin effectively reduced 
admission to hospital due to heart failure compared to 
several other antidiabetics, with estimates consistent with 
previously completed clinical trials.21 Propensity score 
matching facilitated the removal of baseline imbalances 
in disease severity across treatment groups, which allowed 
reliable estimates to be obtained. The removal of baseline 
imbalance was not possible in the study by Freemantle et al, 
however, as imbalances in disease severity could not all be 
captured through simple matching.5 Although the analytical 
approach is important, evaluation of the completeness and 
validity of the recording of the confounding variables and 
risk of unmeasured confounding is equally crucial.17,22 If the 
source of data does not include information on confounding 
variables, as in the study by Freemantle et al,5 it creates a 
problem of unmeasured confounding and will bias analy-
ses.17 Methodological approaches involving the use of proxy 
variables for confounders and sensitivity analysis can be 
considered to explore the impact of unmeasured confound-
ing on the analysis.23 However, despite these approaches, the 
limitations of such a study must be reconsidered, especially if 
unmeasured confounding is suspected to be highly influential.
outcome ascertainment
In any cohort study comparing the effectiveness of different 
treatments, all groups at baseline must have an equal chance 
of recording the outcome being investigated. A thorough 
consideration of whether individuals receiving one treatment 
may have longer follow-up, or are more likely to be screened 
for an event, to be intensively managed or to have better 
data recorded, must be made at the outset.7 For example, 
individuals prescribed the anticoagulant warfarin, which 
requires regular international normalized ratio blood testing, 
as opposed to direct oral anticoagulants, which do not, may 
have more frequent health care contacts and thus greater 
opportunity to report symptoms that lead to identification of 
an outcome being considered, eg, minor stroke. This could 
falsely lead to higher reporting and recording of an outcome 
in the warfarin group, resulting in estimates suggesting that 
warfarin is inferior in effectiveness when this is purely due 
to a reporting bias or an attrition bias (imbalance in the dura-
tion of follow-up).
Case study example
overview
In this case study, we discuss how we applied the consider-
ations detailed in the previous section to design a cohort study 
to compare the effectiveness of two antidiabetic treatments, 
sitagliptin vs sulfonylureas, as add-on to metformin for the 
treatment of type 2 diabetes mellitus. Both treatments are 
widely used add-on options for managing type 2 diabetes 
mellitus when metformin alone has proved inadequate. 
Guidelines from the UK National Institute of Health and 
Care Excellence, as well as other international guidelines, 
do not discriminate between these add-on treatments in terms 
of effectiveness.24 Our study investigated their glycemic 
effectiveness when used as part of routine clinical care in 
UK general practice.
We undertook this study in The Health Improvement 
Network Primary Care Database (version 15), which  contains 
anonymized data from around 670 general practices across 
the UK. Scientific approval to undertake this study was 
obtained from the IQVIA World Publications Scientific 
Review Committee in August 2016 (reference number 
16-072).25 This retrospective cohort study examined changes 
in HbA
1c
 from baseline after 12 months of treatment between 
those prescribed sulfonylurea vs sitagliptin as add-on to 
metformin for type 2 diabetes mellitus. The driver behind 
this study was to investigate the external validity of several 
trials which had concluded that both treatments produced a 
similar glycemic reduction after initiation. Details of how 
we identified individuals with type 2 diabetes mellitus have 
been previously described in depth.26
The baseline characteristics of our cohort, and how this 
cohort study population differed from the corresponding trial 
populations, are shown in Table 2.
In summary, our cohort study population was older, had 
worse baseline HbA
1c
 control and had higher weight than the 
populations in the completed trials.
After adjustment for baseline HbA
1c
, sex, age and other 
identified potential confounders in our analysis, we found 
that 12 months after treatment initiation the HbA
1c
 level was 
on average 1 mmol/mol (mean difference 0.89 mmol/mol, 
95% CI 0.33–1.45) higher for those prescribed sitagliptin 
compared to sulfonylureas (Table 3). Despite its statistical 
significance, a difference of up to 1.45 mmol/mol is not 
considered clinically significant, given than such a small 
quantitative difference in HbA
1c
 would not impact on the 
short- or long-term prognosis of diabetes.24 In fact, clinically 
relevant differences in HbA
1c
 are those that typically exceed 
5.5 mmol/mol and ideally 10.9 mmol/mol in magnitude.27 Our 
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cohort study estimate was found to compare favorably with 
that from the meta-analysis of completed RCT previously 
undertaken (Figure 1), which also highlighted no significant 
difference (weighted mean difference 0.54 mmol/mol, 95% 
CI –0.28 to 1.35).28
Case study in context
We approached the study question having considered each of 
the design issues detailed in the earlier section (see section 
“Important considerations in the design of cohort studies to 
evaluate treatment effectiveness”). Our choice of a new-user 
design was taken to mitigate the risk of prevalent user bias 
that would arise by including individuals who had already 
been exposed to the treatment and hence experienced a gly-
cemic benefit.10 This was achieved by following individuals 
from their first prescription of sitagliptin or sulfonylurea and 
ensuring that they had not been prescribed any antidiabetic 
agents other than metformin in the preceding 12 months.
We chose to use an active comparator in this study to 
mitigate the risk of channeling bias that might have arisen if 
we had compared the treatment group to a non-treated group, 
as there would have been a substantial difference in disease 
severity.5 Both sitagliptin and sulfonylurea are commonly used 
as add-on to metformin in the type 2 diabetes clinical pathway, 
which would help to balance disease severity at baseline. 
Nevertheless, there were differences at baseline between the 
groups in HbA
1c
 and weight, which we believed would influ-
ence both treatment choice and outcome and hence could lead 
to confounding bias. We explored the recording and measure-
ment of these confounders across treatment groups to ensure 
adequacy before controlling for them using a multivariable 
regression model.17 We undertook several sensitivity analyses 
exploring subgroups such as those who persisted with treat-
ment for the study duration to ensure that the findings were 
robust. Finally, to eliminate the risk of recording bias, we 
analyzed both treatment arms to ensure that the frequency of 
HbA
1c
 recording across both groups over time was similar.7
To investigate the robustness of our estimate, we com-
pared our study to the existing literature and highlighted 
how the comparative effectiveness estimate of this cohort 
study compared favourably to a meta-analysis of completed 
RCTs.28 The absolute change in HbA
1c
 observed with both 
treatments, however, was greater in our study than that 
observed in the trials. This may have been due to the fact 
that our baseline population had worse disease (worse 
glycemic control) at treatment initiation than those in the 
previously completed trials, and hence had differential scope 
for improvement.T
ab
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Comparison to previously completed trials is a common 
approach used to demonstrate the validity of results in obser-
vational studies.3 As in our example, the studies by Smeeth 
et al and Patorno et al detailed earlier were able to compare 
their findings to estimates from previously completed tri-
als for consistency.15,21 A comparison trial, however, is not 
always available, and therefore careful consideration of the 
issues outlined in this article can help to ensure a more robust 
approach to designing observational studies of effectiveness 
and mitigating the risk of bias. Equally, traditional challenges 
common to all observational study designs, such as handling 
missing data and the risk of exposure misclassification, 
remain when undertaking cohort studies and must also be 
carefully considered and managed.7,29
Figure 1 Forest plot comparing our case study (Sharma et al) with meta-analyses of previous RCt examining change in hbA1c (mmol/mol) between sitagliptin and 
sulfonylurea as add-on to metformin.
Notes: Weights, where present, are from fixed-effects meta-analysis (Mantel–Haenszel method), although random-effects estimates (DerSimonian–Laird method) were 
identical.
Source: Adapted from Sharma M, Beckley N, Nazareth I, Petersen I. Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled 
on metformin: a systematic review and meta-analysis. BMJ Open. 2017;7(10):e017260.28
Abbreviations: dur, duration; Mean diff, mean difference; Sita, sitagliptin; Sulf, sulfonylureas; tot, total participants; RCt, randomized controlled trial; obs, observational 
study; NA, not applicable.
Study Type Dur Mean MeanTot Tot Mean diff (95% CI) Weight
Sita
SD
Sulf
SD
Ahrén et al30 RCT 24 –3.10 –3.90297 299 0.80 (–1.15, 2.75) 17.4912.2 12.1
Seck et al32 RCT 24 –3.60 –3.80576 559 0.20 (–1.16, 1.56) 36.1811.4 11.9
Arechavaleta
et al31
RCT 7.5 –5.00 –5.70509 509 0.70 (–0.50, 1.90) 46.3310.1 9.4
Sharma et al
(present study)
Obs 12 –9.60 –14.20
–3 –2 –1 0 1 2 3
3306 15880
Favors sita Favors sulf
16.2 20.0
Overall (I2=0.0%, P=0.828) 0.54 (–0.28, 1.35) 100.00
0.89 (0.33, 1.45) NA
Table 3 Results from the case study: analysis of mean difference in hbA1c (mmol/mol) 12 months after initiation of sitagliptin vs 
sulfonylureas
Sitagliptin vs  
sulfonylurea
Unadjusted Adjusted for  
baseline HbA1c
Adjusted for sex, age  
and baseline HbA1c
Fully adjusted  
multivariable modela
Population 
size (n=19,156)
0.55 (−0.04 to 1.13) 1.78 (1.23 to 2.33) 1.13 (0.59 to 1.67) 0.89 (0.33 to 1.45)
Notes: data are shown as the mean difference (95% CI). aAdjusted for potential confounders including baseline hbA1c, baseline weight, age, year of cohort entry, face-
to-face consultation frequency, year of entry, sex, townsend deprivation score, smoking status, metformin dose, alcohol consumption, history of hypoglycemia, chronic 
kidney disease, neuropathy, heart failure, anemias, dementia, liver disease, arrhythmias, cancer, hypothyroidism, hyperthyroidism, pancreatitis, and having a prescription 
within 3 months of treatment initiation for antihypertensives, antiplatelets, anticoagulants, antiarrhythmics, diuretics, statins, other lipid-lowering drugs, antidepressants, 
antipsychotics, antiobesity drugs, oral or intravenous steroid medication, thyroxine, antithyroid drugs or anxiolytics. Individuals prescribed sulfonylureas are the reference 
population in all regression estimates.
Conclusion
In this manuscript, we describe some key considerations for 
clinical researchers that can help to mitigate the risk of bias 
when designing cohort studies evaluating effectiveness. These 
considerations can also help researchers to identify clinical 
questions that are more suited to such a cohort study design. 
Their overall purpose is to ensure that the characteristics of 
groups across which the treatments are being compared are 
as similar as possible at baseline in terms of disease severity 
and, in addition, that the occurrence of the outcome of interest 
is reported equally in all groups. They must also be assessed 
in the context of traditional methodological challenges of 
observational studies, such as the possible existence of miss-
ing data and the risk of exposure misclassification. However, 
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observational studies of treatment effectiveness
despite these obstacles, these considerations can help clinical 
researchers and epidemiologists to identify focused clinical 
questions where observational studies of effectiveness may be 
most worthwhile and, potentially, even advantageous.
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